Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you.
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities.
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless.
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest.
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions.
- Other sectors: From media to academia, we work with sectors as diverse as our data.
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on:
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge.
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them.
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Astrocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Debio-0123 in Astrocytoma Drug Details: Debio-0123 (ADC-730) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Gastric Cancer Drug Details: Tislelizumab (Baizean) is a humanized monoclonal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tislelizumab (Baizean)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mitoxantrone Hydrochloride in Hypopharyngeal CancerDrug Details:Mitoxantrone hydrochloride is a anthracenedione antibiotic with antineoplastic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - TCMCB-07 in Cancer Anorexia-Cachexia Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TCMCB-07 in Cancer Anorexia-Cachexia Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TCMCB-07 in Cancer Anorexia-Cachexia SyndromeDrug Details:TCMCB-07 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Tranexamic acid in Postoperative Ileus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tranexamic acid in Postoperative Ileus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tranexamic acid in Postoperative IleusDrug Details:Tranexamic acid (LB-1148) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - CMK-389 in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CMK-389 in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CMK-389 in Pulmonary Sarcoidosis Drug Details: CMK-389 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - TSR-033 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSR-033 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSR-033 in Metastatic Colorectal Cancer Drug Details: TSR-033 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Balstilimab in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Balstilimab in Angiosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Balstilimab in AngiosarcomaDrug Details:AGEN-2034 (balstilimab) is under development for the treatment of metastatic angiosarcoma, metastatic...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.